GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Humanwell Healthcare Group Co 600079.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

19.52

+0.05%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥23.96bn

FY2016FY2025

Net income

CN¥1.86bn

FY2016FY2025

Free cash flow

CN¥1.79bn

FY2016FY2025

Shareholders' equity

CN¥18.91bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥23.96bnCN¥25.44bnCN¥24.52bnCN¥22.34bnCN¥20.55bnCN¥20.68bnCN¥21.81bnCN¥18.63bnCN¥15.45bnCN¥12.33bn
Gross profitCN¥11.55bnCN¥11.31bnCN¥11.22bnCN¥9.71bnCN¥8.77bnCN¥8.67bnCN¥8.61bnCN¥7.43bnCN¥5.88bnCN¥4.53bn
Research and developmentCN¥1.50bnCN¥1.47bnCN¥1.46bnCN¥966.9mCN¥810.5mCN¥767.5mCN¥591.2mCN¥484.1mCN¥398.5mCN¥502.2m
Operating incomeCN¥3.82bnCN¥2.52bnCN¥3.45bnCN¥3.52bnCN¥2.25bnCN¥2.09bnCN¥1.84bnCN¥1.80bnCN¥3.03bnCN¥1.34bn
Net incomeCN¥1.86bnCN¥1.33bnCN¥2.13bnCN¥2.48bnCN¥1.32bnCN¥1.01bnCN¥842.5m−CN¥2.36bnCN¥2.07bnCN¥832.4m
Diluted earnings per share1.140.821.281.540.820.730.60-1.451.590.64

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥36.75bnCN¥36.51bnCN¥36.20bnCN¥36.02bnCN¥35.41bnCN¥32.42bnCN¥36.05bnCN¥36.18bnCN¥36.27bnCN¥26.43bn
Cash and short-term investments—CN¥4.95bnCN¥5.04bnCN¥6.12bnCN¥6.10bnCN¥6.20bnCN¥4.32bnCN¥4.18bnCN¥4.35bnCN¥3.21bn
Total liabilitiesCN¥14.74bnCN¥15.82bnCN¥16.11bnCN¥18.08bnCN¥19.75bnCN¥19.44bnCN¥21.82bnCN¥21.70bnCN¥19.43bnCN¥14.45bn
DebtCN¥2.43bnCN¥8.41bnCN¥9.95bnCN¥10.25bnCN¥12.97bnCN¥13.42bnCN¥12.14bnCN¥11.68bnCN¥10.22bnCN¥7.88bn
Shareholders' equityCN¥18.91bnCN¥17.62bnCN¥17.04bnCN¥15.04bnCN¥12.95bnCN¥10.64bnCN¥10.17bnCN¥10.82bnCN¥13.52bnCN¥10.04bn
Shares outstanding1,632m1,630m1,663m1,615m1,599m1,378m1,411m1,630m1,303m1,307m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥2.52bnCN¥2.16bnCN¥1.97bnCN¥2.44bnCN¥2.18bnCN¥1.99bnCN¥2.04bnCN¥603.0mCN¥38.2mCN¥526.5m
Capital spending−CN¥732.7m−CN¥1.02bn−CN¥1.96bn−CN¥3.11bn−CN¥1.70bn−CN¥1.10bn−CN¥821.2m−CN¥1.33bn−CN¥1.73bn−CN¥1.24bn
Free cash flowCN¥1.79bnCN¥1.14bnCN¥8.9m−CN¥672.3mCN¥475.8mCN¥890.6mCN¥1.22bn−CN¥731.7m−CN¥1.70bn−CN¥717.8m
Dividends paid−CN¥1.06bn−CN¥1.27bn−CN¥587.7m−CN¥244.7m−CN¥161.0m−CN¥67.0m−CN¥87.2m−CN¥1.04bn−CN¥566.4m−CN¥468.2m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥5.96bnCN¥6.10bnCN¥6.08bnCN¥5.82bnCN¥5.93bnCN¥6.14bnCN¥6.29bnCN¥6.28bn
Gross profitCN¥3.03bnCN¥3.02bnCN¥2.98bnCN¥2.76bnCN¥2.82bnCN¥2.98bnCN¥2.36bnCN¥2.94bn
Operating incomeCN¥1.18bnCN¥1.04bnCN¥906.3mCN¥917.7mCN¥977.2mCN¥857.3mCN¥96.4mCN¥835.5m
Net incomeCN¥741.4mCN¥588.2mCN¥166.8mCN¥533.9mCN¥614.3mCN¥540.3m−CN¥259.9mCN¥478.6m
Diluted earnings per share0.450.360.100.330.380.33-0.160.29
Cash from operations———CN¥829.0mCN¥1.20bn−CN¥336.0m—CN¥647.0m
Capital spending−CN¥170.0m−CN¥92.0m−CN¥104.0m−CN¥247.0m−CN¥131.0m−CN¥249.0m−CN¥226.0m−CN¥256.0m
Free cash flow———CN¥582.0mCN¥1.06bn−CN¥585.0m—CN¥391.0m
Total assetsCN¥37.19bnCN¥37.61bnCN¥36.75bnCN¥36.82bnCN¥37.56bnCN¥37.17bnCN¥36.51bnCN¥37.35bn
Cash and short-term investments———CN¥4.67bnCN¥5.39bnCN¥4.59bnCN¥4.95bnCN¥4.76bn
DebtCN¥2.72bnCN¥2.60bnCN¥2.43bnCN¥7.23bnCN¥9.05bnCN¥8.85bnCN¥8.34bnCN¥8.45bn
Shareholders' equityCN¥19.31bnCN¥19.42bnCN¥18.91bnCN¥18.91bnCN¥18.34bnCN¥18.13bnCN¥17.62bnCN¥17.87bn

Financial ratios

Data as of 22 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin48.2%44.5%45.8%43.5%42.7%41.9%
Operating margin16.0%9.9%14.1%15.7%10.9%10.1%
Net margin7.7%5.2%8.7%11.1%6.4%4.9%
Return on equity9.8%7.5%12.5%16.5%10.2%9.5%
Return on assets5.0%3.6%5.9%6.9%3.7%3.1%
Free cash flow yield10.6%10.4%12.6%18.4%13.0%12.0%
Revenue growth-5.8%3.7%9.8%8.7%-0.6%-5.2%
Earnings growth39.5%-37.7%-14.1%88.6%31.0%19.4%
Current ratio1.83x1.49x1.48x1.28x1.17x1.28x
Debt to equity0.13x0.47x0.54x0.56x0.78x1.17x
Equity ratio51.5%48.3%47.1%41.7%36.6%32.8%
Interest coverage14.11x6.64x8.42x6.98x3.60x2.41x
R&D as a share of sales6.3%5.8%6.0%4.3%3.9%3.7%
Buybacks as a share of market value-0.2%2.0%-2.9%-1.0%-16.0%2.3%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue2.4%3.0%9.1%
Operating income2.8%12.8%14.5%
Net income-9.3%13.0%11.0%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin46.3%45.5%44.5%42.3%
Operating margin12.8%13.8%12.8%12.3%
Net margin6.4%8.1%7.4%5.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings16.028.619.415.527.346.422.6-7.011.231.4
Price to sales1.21.51.71.71.82.30.90.91.52.1

Dividends and splits

Per share, in the currency the company pays

Paid for 6 years. Last went ex-dividend on 3 Aug 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2018
Paid in the year0.480.320.610.160.150.100.050.16
  • 2-for-1 split · 22 Jul 2015
  • 3-for-2 split · 13 Jun 2007
  • 1-to-1 reverse split · 19 Aug 2005
  • 7-for-5 split · 30 May 2003
  • 19-for-10 split · 31 Aug 2000

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.